离岸价格
Get Latest Price|
- Minimum Order
国:
China
モデル番号:
-
离岸价格:
ロケーション:
-
最低注文量の価格:
-
最低注文量:
-
パッケージの詳細:
-
納期:
-
供給能力:
-
支払いタイプ:
-
製品グループ :
-
連絡先担当者 Dong
Road Lingong, Linyi, Shandong
Arena Pharmaceuticals has developed lorcaserin (Lorqess; Belviq; APD***6), the lead from a series of orally active, small-molecule *-HT 2c agonists. Lorcaserin is indicated in the US where it would be marketed by licensee Eisai, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of *0 kg/m2 or greater (obese) or *7 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, dyslipidemia and type 2 diabetes)
| 国: | China |
| モデル番号: | - |
| 离岸价格: | Get Latest Price |
| ロケーション: | - |
| 最低注文量の価格: | - |
| 最低注文量: | - |
| パッケージの詳細: | - |
| 納期: | - |
| 供給能力: | - |
| 支払いタイプ: | - |
| 製品グループ : | - |
